Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
J Urol
; 190(3): 850-6, 2013 Sep.
Article
em En
| MEDLINE
| ID: mdl-23507396
Palavras-chave
AE; AWD; BCG; CR; DLT; IFN; LLOQ; NED; NMIBC; adverse event; alive with disease; bacillus Calmette-Guérin; complete response; dose limiting toxicity; genetic therapy; interferon; interferons; lower limit of quantitation; no evidence of disease; nonmuscle invasive bladder cancer; urinary bladder neoplasms
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Terapia Genética
/
Interferon-alfa
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Limite:
Aged80
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article